Final trial confirms efficacy of Sanofi's dengue vaccine

PARIS (Reuters) – French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros ($1.7 billion) in the project, undertaking two decades…

Source:Final trial confirms efficacy of Sanofi’s dengue vaccine